"Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients"
http://www.nejm.org/doi/full/10.1056/NEJMoa1300955?query=featured_home
"CONCLUSIONS
Among participants with atherosclerotic vascular disease, the addition of extended-release niacin–laropiprant to statin-based LDL cholesterol–lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.)"
No comments:
Post a Comment